[DArg10, Aib20] TLQP-21

[DArg10, Aib20] TLQP-21 (1 mM) shows drastically improved stability in mouse plasma with a half-life of 253 minutes^[1].
[DArg10, Aib20] TLQP-21 induces β-arrestin recruitment in HTLA cells expressing human C3aR1 with an EC₅₀ of 854 nM and an E_max of 93.65% of basal levels^[1].
[DArg10, Aib20] TLQP-21 activates Gi3 signaling in HEK293T cells expressing human C3aR1 with an EC₅₀ of 1715 nM and an E_max of 62.6% of C3a_63-77 activity^[1].
[DArg10, Aib20] TLQP-21 promotes β-arrestin association with human C3aR1 in HEK293T cells with an EC₅₀ of 1007 nM and an E_max of 71% of C3a_63-77 activity^[1].
[DArg10, Aib20] TLQP-21 does not induce calcium influx in 3T3-L1 cells, but acts as a functional antagonist with an IC₅₀ of 1.7 μM for inhibiting TLQP-21-mediated calcium influx via a β-arrestin-dependent mechanism^[1].
[DArg10, Aib20] TLQP-21 (1-100 μM) does not induce degranulation in LAD2 human mast cells at doses up to 100 μM, but dose-dependently inhibits C3a_63-77- and compound 48/80-mediated degranulation^[1].
[DArg10, Aib20] TLQP-21 (100 nM-10 μM; 1-3 hours) does not potentiate isoproterenol-induced lipolysis in 3T3-L1-derived adipocytes, but inhibits TLQP-21-mediated potentiation of this lipolytic response at 10 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.